Taiwan's PharmaEngine submits NDA at home for MM-398 pancreatic cancer candidate

Taiwan's PharmaEngine submitted a New Drug Application to the Taiwan Food and Drug Administration for MM-398 to treat patients with metastatic adenocarcinoma of the pancreas. The move follows a NDA and marketing authorization application by its licensing partner, Merrimack Pharmaceuticals ($MACK), and sublicensing partner, Baxter International's ($BAX) BioScience business to the U.S. FDA and to the European Medicines Agency, respectively. Release